Research and Clinical Trials

Title  
Ibudilast for ALS
Brief Description  
To see if ibudilast is safe to take and doesn't have too many side effects, and can help people with ALS in slowing down the progression of the disease. Subjects will be randomly assigned in a 2:1 ratio to ibudilast or placebo. Ibudilast and placebo are in pill form and are taken daily by mouth. For Part 1 of study, subjects will remain on ibudilast or placebo for six months. For Part 2, people who were assigned to take placebo during Part 1 will take ibudilast for 6 months;
Who may be Eligible  
18 years of age or older; be diagnosed with familial or sporadic ALS
Start Date  
08/20/2014
IRB Number  
08-14-07B
Principal Investigator  
Brooks, Benjamin
Contact Name  
Cynthia

For More Information, Contact  Cynthia  , Lary
Phone:  (704) 446-6063  Fax:  (704) 446-6208  
Email:  Cynthia.lary@carolinashealthcare.org
Address:Carolinas Neuromuscular/ALS-MDA Center, CMC-Neurology 1010 Edgehill Road, N Charlotte, NC 28207
Close